Evidence map›Paper›PMID 40418207›Full record

ArticleHuman vaccines & immunotherapeutics2025

Research trends in anti-rabies virus monoclonal antibody: A bibliometric analysis.

Cheng Liu, Xinjun Lv, Si Liu, Qingjun Chen, Zhenggang Zhu, Rui Yu, Wenwu Yin, Chuanlin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cheng LiuDepartment of Emergency, Peking University First Hospital, Beijing, China.
Xinjun LvNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Si LiuDepartment of Emergency, Peking University First Hospital, Beijing, China.
Qingjun ChenDepartment of Emergency, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Zhenggang ZhuImmunization Planning Institute, Wuhan Center for Disease Control and Prevention, Wuhan, China.
Rui YuImmunization Department, Beijing Center for Disease Control and Prevention, Beijing, China.
Wenwu YinDivision of Infectious Disease Management, Chinese Center for Disease Control and Prevention, Beijing, China.
Chuanlin WangDepartment of Emergency Surgery, Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rabies is a fatal zoonotic infectious disease primarily caused by the rabies virus. Anti-rabies monoclonal antibody (mAb) is developed using modern genetic engineering technology. However, no bibliometric assessment has been conducted to evaluate the scientific progress in this area. A search of articles in the Web of Science (WoS) from January 1, 1991, to November 17, 2024, yielded 455 papers that were analyzed using various online analysis tools. The cumulative publications from 1991 to 2023 followed a linear distribution. The United States and China led this research initiative. Keywords were divided into two clusters, including "monoclonal-antibody" and "post-exposure prophylaxis." This systematic bibliometric analysis of the literature on anti-rabies monoclonal antibodies will help to reveal the internal relationship of the whole research and development network and promote the perfection of related research and development work to a considerable extent. This study not only delineates the historical trajectory and current status of mAb research but also provides valuable insights and concrete recommendations for future directions.

Indexed as

Antibodies, MonoclonalAntibodies, ViralBibliometricsBiomedical ResearchRabiesRabies virusAnimalsHumansPost-Exposure ProphylaxisUnited StatesAntibodies, MonoclonalAntibodies, Viralbibliometric analysismonoclonal antibodypost-exposure prophylaxisRabies virusvaccine

Identifiers

PMID40418207
PMCPMC12118409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.